Introduction
Given their distinct oncogenic and mutational pathways (1, 2) , head and neck squamous cell cancers (HNSCCs) may differentially respond to radiation and/or chemotherapy. Existing reports indicate that treatment outcomes depend on the p53 mutational status and HPV oncogene expression (3) (4) (5) . To better understand HNSCC biology, several models exist to study the development of autochthonous head and neck tumors. Many groups have relied on chemical carcinogens such 4-Nitroquinolone 1-oxide (4-NQO) to induce cancers with undefined DNA lesions that mimic those caused by cigarette smoking (6, 7) . To generate tumors with more homogeneous genetic profiles, other groups have genetically engineered mice to overexpress mutant cellular oncogenes such as KRAS (8) or to delete tumor suppressors such as p53 (9) (10) (11) (12) . Furthermore, groups have engineered mice to express some of these oncogenes in a spatio-temporal manner using systems such as ligand regulated Cre recombinases (8, 9, 13) .
However, understanding how other oncogenes such as the HPV oncogenes E6
and E7 (E6E7) (14) impact oral tumor responses to therapy are limited by the availability preclinical models, the accurate delivery of radiotherapy and the assessment of treatment responses. While several xenotransplant models exist for HPV-associated tumor development. In addition, irradiation of oral tumors has been limited to 2 to 6 Gy due to the proximity of tumors to the central nervous system and other vital structures (17 ). Finally, monitoring treatment responses to autochthonous oral tumors has been mostly constrained to crude measurements such as survival and weight loss. Thus, understanding how the tumor genotype dictates response to therapy would benefit from novel preclinical models that monitor the response of primary HPV-positive tumors to radiation and other targeted therapies.
Here, we developed a novel head and neck tumor model to monitor the growth of HPV-positive tumors and their response to therapy using bioluminescence. We used a ligand-regulated Cre recombinase to induce the HPV oncogenes E6E7 and a luciferase reporter in vitro and in vivo. Oral tumors arose in mice when E6E7 and mutant
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oncogenes were induced in the basal epithelial layer. These oral tumors expressed HPV-associated biomarkers and grew faster than tumors arising in control mice harboring only a mutant KRAS oncogene. HPV-tumors gained bioluminescence over time which was modulated by tumoricidal agents including small molecule inhibitors and image guided radiotherapy (IGRT).
Methods
Generation of iHPV-Luc Transgenic Vector and Mice
The pB-actin E6E7 plasmid containing the HPV-16 E6E7 was a generous gift Peripheral blood lymphocytes were isolated by retroorbital bleeding and red blood cells were lysed with RBC lysis buffer (eBioscience). Cells were analyzed by FACscan and data was analyzed by FlowJo software. 6 293 HEK cells were transfected with iHPV-Luc vector with or without iCre vector using Fugene HD (Promega). 48h later cells were trypsinized and lysed with a modified radio-immunoprecipitation assay buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 μM EDTA, 1% NP40, 1 μg/ml aprotinin, 1 μg/ml leupeptin, and 10 μM PMSF) for 30 min on ice. Samples were subjected to SDS-PAGE using a 4% stacking gel and a 10% resolving gel. The protein gel was then transferred to nitrocellulose, blocked, and probed using a 1:200 dilution of primary antibody and subsequently a 1:1000 dilution of a secondary HRP conjugated goat anti-rabbit IgG antibody (Pierce, Rockford, IL). The membrane was developed using ECL (Amersham, Arlington Heights, IL). assessed using a Turner TD 20/20 Luminometer (Turner Designs) and luciferase activity was normalized to protein concentration of the sample.
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In vivo Imaging
Luciferase activity was measured noninvasively using the IVIS-200 imaging system (Caliper LifeSciences). Mice were injected i.p. with luciferin (300 mg/kg dissolved in PBS; Caliper) and anesthetized via inhaled 3% isoflurane (Abbott Laboratories Ltd.). Exposure time for all images ranged from 1 to 5 s. All images were analyzed using Living Image software (Caliper) with a binning of 8. In vivo bioluminescent signal was quantified by taking the total photon counts for each region of interest.
Histology
Tumors were isolated and placed into 4% paraformaldyhyde solution for 24h and then dehydraded with 70% ethanol. Tissues were embedded in paraffin, sectioned and stained with hematoxyalin-eosin or the indicated antibodies at the University of Chicago Immunohistochemistry core facility.
Excision KRAS specific PCR
For detection of iE6E7 recombination, tumors were digested in lysis buffer supplemented with proteinase K and genomic DNA was isolated from tumors using 
Image guided radiotherapy (IGRT)
Mice bearing 14-21d old tumors were irradiated using an XRAD 225Cx (Precision Xray, North Branford, CT) small animal image guided irradiator. Anesthetized mice were immobilized in the supine position and a cone beam CT was obtained using 40 kVp and 250 mA. For each mouse, the isocenter was placed in the mid-point of the tumor and anterior to the mouth in order to cover the oral tumor using half of a 1.5 cm collimator. A radiation dosimetry plan was generated using opposed lateral fields. Mice were treated with 225 kVp X-rays at 13 mA to a dose of 20 Gy.
In vivo tumor growth
Tumors were measured every three days. Given the ellipsoid growth of oral tumors, we reasoned that the oral tumor volume would approximate a solid ellipsoid 
Generation of an autochthonous oral HPV-tumor model
We next generated mice that developed autochthonous HPV-positive oral tumors. Based on previous reports, mice induced to express the KRAS 
KHR tumor growth was associated with increase bioluminescence
We then assessed the kinetics of bioluminescence after tamoxifen treatment ( Fig   4A) . Within 3d of initiating Tam treatment, mice had increased bioluminescence compared to untreated mice. By 24d after Tam treatment, KHR mice had 65.7-fold higher bioluminescent signal compared to untreated controls (Fig. 4B) . KHR mice that developed oral tumors had progressively increasing oral bioluminescence that correlated with tumor growth (P < .0001, r = 0.88; Fig. 4C ). By contrast, bioluminescence around the oral cavity plateaued in KH mice within 6 days at 7.4-fold above background. KR mice treated with Tam developed oral tumors that did not possess bioluminescence signal above background.
In vivo bioluminescent monitoring of response to tumoricidal agents
Since bioluminescent signal correlated with tumor volume, we tested the extent to which bioluminescent signal in autochthonous tumors would enable monitoring response to agents that impacted tumor growth (9) . Rapamycin has been shown to impact the growth in autochthonous oral tumor models driven by a mutant KRAS, in transplanted head and neck squamous cell carcinoma models and in clinical trials. 14d
after Tam treatment, we treated KHR mice with rapamycin for 3 days and monitored tumor growth. Compared to the vehicle treated controls, mice treated with rapamycin had a transient decrease in tumor growth with regrowth after rapamycin was discontinued ( Since oral tumors in KHR mice possessed decreased bioluminescence that correlated with rapamycin treatment, we next tested the extent to which IGRT impacted KHR tumor growth and bioluminescence (Fig. 6) . IGRT is rapidly being implemented in the clinic to treat HNSCC patients given the increased ability to target tumors (23). As in patients, cone beam CT images were obtained for each tumor and the isocenter was placed according to the tumor extent ( Fig 6A) . We developed individual radiotherapy plans using opposed lateral radiation beams to treat mice to 20 Gy. 14d after Tam treatment, mice were irradiated with 20 Gy and tumors regressed ( 
invasive disease. Finally, HPV-positive mice developed oral tumors and not oropharyngeal cancers that are seen in HNSCC patients. Still, these oral tumors occurred at murine anatomic sites with epithelial transitional zones that are classically affected by HPV oncogenes (29) .
As in previous models (8, 9), we used a tamoxifen-regulated Cre recombinase expressed in the basal epithelial layer in order to induce HPV-positive oral tumors.
Previous models of autochthonous oral tumors have relied on chemical carcinogens (6) or genetically engineered transgenes (8, 9, 13) . These genetically defined models expressed mutant KRAS and/or mutant p53 as well as deleted NOTCH1 (12) and/or TGFβR1 (11). In addition, mouse models with inducible promoters have been used to drive oncogenes in the basal epithelial layer resulting in squamous tumors (30, 31) . Recently, several groups have treated autochthonous sarcomas and non-small cell lung cancers as well as normal tissues (8, (48) (49) (50) . However, irradiation of these tumors at most resulted in growth arrest while, in our model, we observed tumor regression. While previous studies treated the head and neck region with low doses of radiation, we were able to deliver therapeutic doses of radiation using IGRT. Furthermore, IGRT will enable 
